Stefan S.
- Country
- Germany
- Department
- NA
Research Overview
- Phase 3b, Randomized, Open‑Label, Active‑Controlled Trial Comparing Guselkumab Versus Risankizumab for Efficacy and Safety in Moderately to Severely Active Crohn’s Disease
- Phase 3 Randomized Double‑Blind Study Evaluating Efficacy and Safety of JNJ‑78934804 Combination Therapy versus Guselkumab in Moderately to Severely Active Crohn’s Disease
- Phase 3 Randomized Double‑Blind Trial of JNJ‑78934804 Combination Therapy vs Guselkumab in Moderately to Severely Active Ulcerative Colitis
Data & Insights
Has run more than one trial at 199 of 321 partner sites.
Specializations
Inflammatory Bowel Disease Management
This investigator specializes in treating inflammatory bowel diseases, with particular emphasis on both ulcerative colitis and Crohn's disease. Their research encompasses various therapeutic approaches for managing these chronic conditions.
- Moderate to Severe Ulcerative Colitis Treatment
- Crohn's Disease Therapy
- Long-term Disease Management
Novel Therapeutic Approaches
The investigator focuses on evaluating innovative biological therapies and their combinations, including studies with risankizumab, guselkumab, and golimumab for inflammatory bowel conditions.
- Combination Therapy Assessment
- Biological Treatment Evaluation
- Treatment Response Monitoring
Clinical Safety and Efficacy
Their research includes comprehensive evaluation of long-term safety profiles and therapeutic efficacy of various treatments for inflammatory bowel conditions, with particular attention to sustained clinical responses.
- Safety Profile Assessment
- Extended Treatment Outcomes
- Therapeutic Drug Monitoring
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.